|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S1
|
$121,550
|
$1,216
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S2
|
$60,000
|
$600
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S3
|
$125,625
|
$1,256
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S4
|
$200,000
|
$2,000
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S5
|
$484,876
|
$4,849
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-37S6
|
$502,500
|
$5,025
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
4P30CA016359-37
|
$2,600,006
|
$26,000
|
SCHULAM, PETER
|
YALE UNIVERSITY
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
2P30CA134274-09
|
$2,259,773
|
$45,195
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-09S1
|
$124,964
|
$2,499
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-09S2
|
$200,219
|
$4,004
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-09S3
|
$629,550
|
$12,591
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Understanding resistance in the HER2-HER3 tumor drive
|
4R01CA122216-09
|
$298,554
|
$74,639
|
MOASSER, MARK
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Tumor-targeted Polymersomes to image and Treat Ovarian Cancer
|
4R01CA175480-04
|
$327,652
|
$163,826
|
CHENG, ZHILIANG
|
UNIVERSITY OF PENNSYLVANIA
|
|
Tumor priming sequences combined with novel nanoparticle drug carriers for enhanced therapeutic efficacy in pancreatic cancer: a tripartite USA/Northern Ireland/Republic of Ireland consortium
|
5R01CA198096-02
|
$429,377
|
$141,694
|
STRAUBINGER, ROBERT
|
STATE UNIVERSITY OF NEW YORK AT BUFFALO
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
5R01CA070375-20
|
$256,101
|
$128,051
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY
|
|
Therapeutic Targeting Agents for Ovarian Cancer
|
5R01CA115483-12
|
$337,307
|
$337,307
|
LAM, KIT
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
Theranostic nanoparticles for the treatment of RAI refractory thyroid cancer
|
4R01CA178007-04
|
$351,713
|
$175,857
|
JIN, MOONSOO
|
WEILL MEDICAL COLL OF CORNELL UNIV
|
|
The Role of USP22 in Prostate Cancer Development and Progression
|
1F99CA212225-01
|
$45,076
|
$13,523
|
MCCANN, JENNIFER
|
THOMAS JEFFERSON UNIVERSITY
|
|
The Role of SRC-1 in Breast Cancer
|
4R01CA112403-10
|
$269,732
|
$67,433
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
The role of ENF loss, TLR4 and spinal plasticity in paclitaxel CIPN
|
1R01CA200263-01A1
|
$494,883
|
$494,883
|
DOUGHERTY, PATRICK
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The mechanism of DNA damage and chromothripsis from chromosome segregation errors
|
1K08CA208008-01
|
$177,120
|
$177,120
|
SPEKTOR, ALEXANDER
|
DANA-FARBER CANCER INST
|
|
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
|
ZIA SC 010098
|
$637,176
|
$31,859
|
Dahut, William
|
CCR (NCI)
|
|
Targeting Stromal Collagen in Pancreatic Cancer
|
4R01CA169281-04
|
$386,727
|
$193,364
|
HAN, HAIYONG
|
TRANSLATIONAL GENOMICS RESEARCH INST
|
|
Targeting PHD2 in Pancreatic Cancer
|
5R21CA191923-02
|
$242,730
|
$60,683
|
HAN, HAIYONG
|
TRANSLATIONAL GENOMICS RESEARCH INST
|
|
Targeting microtubule stabilization to reduce breast tumor metastasis
|
4R01CA154624-05
|
$318,513
|
$159,257
|
MARTIN, STUART
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Targeting BET proteins in Triple Negative Breast Cancer
|
1R01CA206505-01
|
$373,968
|
$186,984
|
KERI, RUTH
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeted Nanotherapy for Pancreatic Cancer
|
1R01CA210192-01
|
$347,700
|
$173,850
|
CHAUHAN, SUBHASH
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
Targeted Combination Therapy for Breast Cancer
|
5R01CA174305-03
|
$313,504
|
$313,504
|
LI, SONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Taccalonolides: Mechanisms of Action and Cellular Resistance
|
4R01CA121138-11
|
$257,668
|
$64,417
|
MOOBERRY, SUSAN
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
Stimuli-responsive crosslinked theranostics against advanced prostate cancer
|
5R01CA199668-02
|
$359,138
|
$118,516
|
LI, YUANPEI
|
UNIVERSITY OF CALIFORNIA AT DAVIS
|
|
Stanford Cancer Institute
|
2P30CA124435-09
|
$3,345,301
|
$33,453
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
|
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer
|
3P50CA070907-18S1
|
$750,052
|
$37,503
|
MINNA, JOHN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer
|
5P50CA070907-18
|
$2,162,000
|
$108,100
|
MINNA, JOHN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
SPORE: Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
|
4P50CA168504-04
|
$2,161,168
|
$64,835
|
WINER, ERIC
|
DANA-FARBER CANCER INST
|
|
SPORE in Breast Cancer
|
3P50CA098131-15S1
|
$750,000
|
$187,500
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
SPORE in Breast Cancer
|
5P50CA098131-15
|
$2,162,000
|
$540,500
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Single Cell In Vivo Imaging Technology to Analyze Taxane Nano Formulations in Breast Cancer
|
1K99CA207744-01
|
$179,280
|
$179,280
|
MILLER, MILES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
SBIR PHASE II PERIOD OF PERFORMANCE 7/16/2016 - 7/15/2018
|
261201500018C
|
$1,984,617
|
$496,154
|
UNKNOWN, UNKNOWN
|
TARGAGENIX, INC.
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S1
|
$131,625
|
$1,316
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S2
|
$118,659
|
$1,187
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S3
|
$99,902
|
$999
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S4
|
$199,940
|
$1,999
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S5
|
$447,972
|
$4,480
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S6
|
$31,320
|
$313
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
3P30CA016056-39S7
|
$749,842
|
$7,498
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Roswell Park Cancer Institute Cancer Center Support Grant
|
5P30CA016056-39
|
$4,021,233
|
$40,212
|
JOHNSON, CANDACE
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Role of Oncogenic Kinase Pim-1 in Prostate Cancer
|
5R01CA123484-09
|
$284,744
|
$71,186
|
ABDULKADIR, SARKI
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Role of Axl in docetaxel resistance in prostate cancer
|
5R21CA187843-02
|
$160,515
|
$160,515
|
LIBERMANN, TOWIA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-08
|
$462,791
|
$231,396
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
PSMA Targeted Docetaxel Loaded Magnetic Nanoparticles for Prostate Cancer Therapy
|
5K22CA174841-02
|
$161,695
|
$161,695
|
YALLAPU, MURALI
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
Total relevant funding to Taxol for this search: $16,913,742
|